Amgen (AMGN) 10-K2021 FY Annual report

Filed: 16 Feb 22, 4:39pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: adapt, adapted, agenda, AIN, Aircraft, Albany, AMGEVITA, AMJEVITA, anti, antigen, arose, art, assay, Authorisation, autoimmune, baseload, batch, bemarituzumab, beneficiary, biennial, binding, booster, cargo, Carolina, catastrophic, CCPA, CEO, CIT, climate, Commissioner, convened, Cosentyx, crowded, Daiichi, decade, dedicated, deepen, degradation, delta, developmental, discarded, distinguish, domain, DoR, easily, Efavaleukin, Enrichment, erosion, ESG, Ethical, exploiting, FASPRO, fellowship, firmly, flat, fluoropyrimidine, FOMBPR, friendly, FTC, GEJ, gradual, guard, hand, headquartered, HeFH, hesitancy, highlighting, HLE, HoFH, Holly, Howard, ID, ILA, inflationary, intentionally, invisible, ishrak, ITP, journey, Juan, Khosla, KKC, Kyowa, lab, Lazard, leucovorin, link, Longshoremen, malfunctioned, maritime, mCRPC, Merger, merit, modality, multispecific, mutein, nasal, Neumora, oldest, omar, omicron, orderly, Ordesekimab, overexpressing, overrun, oxaliplatin, paired, palmoplantar, PDUFA, persistent, Ph, phaseout, poll, port, Prime, promptly, Rachna, reconciliation, redesign, redesigning, reliant, repeated, Rescue, RIABNI, robust, Salomon, Sankyo, scheme, Skyrizi, SOFR, splenectomy, strike, substance, Suisse, suppressed, Taltz, tangibly, Tarlatamab, Teneobio, TEZSPIRE, TNF, Tremfya, tropical, Tuxedo, ulcerative, underrepresented, unexpired, unreliability, upward, Urban, urticaria, variant, viable, Virginia, visible, Win, WISE, withdrew, worth, Zone

Removed: activator, adalimumab, administering, Ajanta, AMGEVITATM, AMJEVITATM, Amsterdam, array, assert, bench, bevacizumab, billing, blueprint, Breckenridge, Cadila, Calcium, carcinoma, cardiovascular, children, cholesterol, comparability, compute, computed, computing, Consulting, convertase, Corlanor, Cosmetic, counterclaimed, curve, declaration, differentiated, disclose, dismissing, disposable, Dissolution, Eli, ErelziTM, ESRD, familial, forma, FZE, heard, horizon, humanized, hypercholesterolemia, ideation, immunotherapy, inequitable, infliximab, innopharma, Inspector, iodine, ivabradine, Johnson, keytruda, kidney, laherparepvec, Lastly, leasing, lieu, lipoprotein, liver, lymphoma, MAA, mecarbil, Medicinal, melanoma, Micro, mortgage, narrowing, Nexavar, NIVESTYMTM, omecamtiv, oncolytic, parent, pembrolizumab, percent, Piacquad, pilot, Piramal, plc, POMALYST, post, preacquisition, preexisting, prepayment, Pro, proprotein, pte, Qilu, radioactive, recording, Reddy, registrational, relieved, remeasure, remission, replacing, responding, retrofitting, revalued, rituximab, Sagent, simplex, solicited, stop, suicidal, Sun, talimogene, Thrombopoietic, thyroid, translating, transplantation, trastuzumab, twelve, UK, unaudited, unclean, underway, undisclosed, unenforceability, vacate, vigorously, Zarxio

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

AMGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 10.23

THIRD AMENDMENT TO THE

AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN

AS AMENDED AND RESTATED EFFECTIVE OCTOBER 16, 2013

The Amgen Nonqualified Deferred Compensation Plan, as Amended and Restated Effective October 16, 2013 (the “Plan”), is hereby amended, effective January 1, 2022, as follows:

1.Section 3.3 (“Delayed Commencement Election”) is amended by adding the following at the end thereof:

The opportunity to delay the effective date of deferral elections as described in this Section 3.3 applies to Plan Years beginning prior to January 1, 2022. In no event may a Participant delay the effective date of his or her deferral elections for Plan Years beginning on or after January 1, 2022.

2.Section 4.1 (“Short-Term Payout”) is amended by adding the following at the end thereof:

The ability to irrevocably elect a Short-Term Payout for Annual Deferral Amounts as described in this Article 4 applies to Plan Years beginning prior to January 1, 2022. In no event may a Participant elect a Short-Term Payout for Annual Deferral Amounts for Plan Years beginning on or after January 1, 2022.

To record this Third Amendment to the Plan as set forth herein, the Company has caused its authorized officer to execute this document this 25th day of October, 2021.

AMGEN INC.

By: /s/ Lori A. Johnston

Name: Lori A. Johnston

Title: Executive Vice President, Human Resources